RxDoctor Payments Data

Joseph Baker, MD

Internal Medicine · Rome, GANPI 1396805644

Payments from drug & device makers

$945in general payments, 2019–2025

Across 59 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$378
  • Covidien LP$97
  • Lilly USA, LLC$81
  • AstraZeneca$58
  • Boehringer Ingelheim$55
  • Sunovion Pharmaceuticals Inc.$53
  • plus $223 from 9 others

What the payments were for

  • Food & beverage$944100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$945 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$375,361
Medicare patients
1,177
Services billed
26,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$173,591
OzempicSemaglutide121$151,570
JardianceEmpagliflozin146$147,957
JanuviaSitagliptin Phosphate152$134,877
TrulicityDulaglutide77$108,169
MounjaroTirzepatide93$106,173
FarxigaDapagliflozin Propanediol81$65,297
XareltoRivaroxaban52$50,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$48,472
ProliaDenosumab19$32,170
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$31,445
LinzessLinaclotide29$21,878
Spiriva RespimatTiotropium Bromide26$19,003
Lantus SolostarInsulin Glargine,hum.Rec.Anlog114$18,214
Tresiba Flextouch U-100Insulin Degludec19$16,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$81$214,342170 claims
PfizerEliquis, Premarin$15$179,459196 claims
Boehringer IngelheimJardiance, Spiriva Respimat$55$166,960172 claims
Novo NordiskOzempic$40$151,570121 claims
AstraZenecaFarxiga, Symbicort$58$77,999114 claims
Johnson & JohnsonXarelto$43$50,08352 claims
AbbVieLinzess, Synthroid$378$28,634132 claims
Astellas Pharma US IncMyrbetriq$47$16,05129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →